Skip to main content
. Author manuscript; available in PMC: 2007 Jan 4.
Published in final edited form as: Endocr Pract. 2006;12(Suppl 1):20–24. doi: 10.4158/EP.12.S1.20

Fig. 1.

Fig. 1

Cumulative incidence of diabetes, stratified by treatment group, for the four-arm Diabetes Prevention Program, including the troglitazone treatment group (N = 2,343). Troglitazone (TROG) versus placebo (PLAC), P<0.001; troglitazone versus metformin (MET), P = 0.02; troglitazone versus intensive lifestyle (ILS), P = 0.18. Adapted from Knowler et al (Diabetes Prevention Program Research Group) (6).